Dataset Information

Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin.

ABSTRACT: BACKGROUND:Cancer is a significant health threat in cats. Chemoresistance is prevalent in solid tumors. The ionophore salinomycin has anti-cancer properties and may work synergistically with chemotherapeutics. The purpose of our study was to determine if salinomycin could decrease cancer cell viability when combined with doxorubicin in feline sarcoma and carcinoma cells. RESULTS:We established two new feline injection-site sarcoma cell lines, B4 and C10, and confirmed their tumorigenic potential in athymic nude mice. B4 was more resistant to doxorubicin than C10. Dose-dependent effects were not observed until 92??M in B4 cells (p =?0.0006) vs. 9.2??M (p =?0.0004) in C10 cells. Dose-dependent effects of salinomycin were observed at 15??M in B4 cells (p =?0.025) and at 10??M in C10 cells (p =?0.020). Doxorubicin plus 5??M salinomycin decreased viability of B4 cells compared to either agent alone, but only at supra-pharmacological doxorubicin concentrations. However, doxorubicin plus 5??M salinomycin decreased viability of C10 cells compared to either agent alone at doxorubicin concentrations that can be achieved in vivo (1.84 and 4.6??M, p

SUBMITTER: Borlle L

PROVIDER: S-EPMC6346515 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin.

Borlle Lucia L Dergham Abdo A Wund Zacharie Z Zumbo Brittany B Southard Teresa T Hume Kelly R KR

BMC veterinary research 20190124 1

<h4>Background</h4>Cancer is a significant health threat in cats. Chemoresistance is prevalent in solid tumors. The ionophore salinomycin has anti-cancer properties and may work synergistically with chemotherapeutics. The purpose of our study was to determine if salinomycin could decrease cancer cell viability when combined with doxorubicin in feline sarcoma and carcinoma cells.<h4>Results</h4>We established two new feline injection-site sarcoma cell lines, B4 and C10, and confirmed their tumori ...[more]

PMID: 30678671

Similar Datasets

Project description:Drug resistance is a prevalent phenomenon that decreases the efficacy of cancer treatments and contributes to cancer progression and metastasis. Weakening drug-resistant cancer cells prior to chemotherapy is a potential strategy to combat chemoresistance. One approach to damage resistant cancer cells is modulation of nutritional intake. The combination of nutrient restriction with targeted compound treatment results in pronounced molecular changes. This study provides valuable information about augmenting existing chemotherapeutic regimes with simultaneous glucose restriction and autophagy inhibition in colorectal cancer cells. In this study, we explore the chemical pathways that drive the cellular response to nutrient restriction, autophagy inhibition, and the chemotherapy irinotecan using global quantitative proteomics and imaging mass spectrometry. We determined that significant pathways were altered including autophagy and metabolism via glycolysis, gluconeogenesis, and sucrose degradation. We also found that period circadian clock 2 (PER2), a tumor suppressor protein, was significantly up-regulated only when glucose was restricted with autophagy inhibition and chemotherapy. The upstream regulators of these differentially regulated pathways were determined to have implications in cancer, showing an increase in tumor suppressor proteins and a decrease in nuclear protein 1 (NUPR1) an important protein in chemoresistance. We also evaluated the phenotypic response of these cells and discovered autophagy inhibition and chemotherapy treatment increased apoptosis and decreased cell clonogenicity and viability. When glucose restriction was combined with autophagy inhibition and chemotherapy, all of the phenotypic results were intensified. In sum, our results indicate that glucose metabolism is of great importance in the ability of cancer cells to survive chemotherapy. By weakening cancer cells with glucose restriction and autophagy inhibition prior to chemotherapy, cancer cells become more sensitive to therapy.

Dataset Information

Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin.

Publications

Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets